Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
3 hedge funds and large institutions have $40.9K invested in Medicenna Therapeutics Corp. Common Shares in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 23 closing their positions.
88% less funds holding
Funds holding: 25 → 3 (-22)
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 23
98% less capital invested
Capital invested by funds: $2.41M → $40.9K (-$2.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
+$3.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.27M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$311K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$223K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$187K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$159K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | -$211 | -715 | Closed |
|
MDNA Hedge Fund Activity: Q4 2023 in Review
3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q4 2023, worth a combined $40.9K — down 98% from $2.41M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MDNA and 1 opened new positions — a net loss of 22 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Newman Dignan & Sheerar Inc, opening a new position worth an estimated $3.45K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.27M sold.
- 3 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q4 2023, down from 25 in Q3 2023.
- Funds reported $40.9K of Medicenna Therapeutics Corp. Common Shares stock for Q4 2023, down 98% quarter-over-quarter.
- 1 fund opened new Medicenna Therapeutics Corp. Common Shares positions in Q4 2023 and 23 closed out, a net change of -22 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q4 2023 was Newman Dignan & Sheerar Inc, an estimated $3.45K added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q4 2023 was AIGH Capital Management, an estimated $1.27M sold.
Based on aggregated 13F filings for Q4 2023.